Research Article Details
| Article ID: | A13896 |
| PMID: | 29704818 |
| Source: | Cytokine |
| Title: | Serum C1q/TNF-related protein 9 is not related to nonalcoholic fatty liver disease. |
| Abstract: | AIMS: C1q/TNF-related protein 9 (CTRP9) is an adipokine mainly secreted by white adipose tissue and plays protective roles in energy metabolism. However, information regarding the role of CTRP9 in nonalcoholic fatty liver disease (NAFLD) is scarce. Here we aimed to ascertain the clinical relevance between circulating CTRP9 levels and NAFLD through a cross-sectional study. METHODS: The study enrolled 82 NAFLD adults and 79 sex- and age-matched non-NAFLD controls. Serum CTRP9 was measured via ELISA method. Metabolic parameters were also determined. RESULTS: Although serum CTRP9 level seems to be higher in NAFLD adults, there was no significant difference among the ultrasonographic degrees of NAFLD (P = 0.275). Further, after adjustment for BMI in the multinomial logistic regression model, no significant odds ratio difference was observed for NAFLD among the CTRP9 tertiles. Moreover, binary logistic regression models demonstrated that, body mass index (BMI) and alanine aminotransferase (ALT) but not CTRP9 were independent factors related to NAFLD. Besides, serum CTRP9 was positively correlated with BMI, waist circumference, Fasting insulin, HbA1c, and HOMA-IR in all subjects. BMI was the independent factor associated with serum CTRP9. CONCLUSIONS: Serum CTRP9 is not independently related to NAFLD. The association between serum CTRP9 and NAFLD might be due to the influence of obesity. |
| DOI: | 10.1016/j.cyto.2018.04.019 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |